Publications by authors named "Lucia Lopez-Granados"
Article Synopsis
- Hypogammaglobulinemia is common in pediatric patients following allogeneic hematopoietic stem cell transplantation (HSCT), often requiring immunoglobulin replacement therapy to prevent infections, especially when it persists over time.
- A study from 2008-2019 evaluated pediatric patients with persistent chronic hypogammaglobulinemia, analyzing the transition from intravenous immunoglobulin (Privigen®) to subcutaneous immunoglobulin (Hizentra®) and its effects on patients’ quality of life.
- The findings indicate that chronic hypogammaglobulinemia results from various factors, and while the study had a small sample size, switching to Hizentra 20% significantly improved the patients
Three new therapies for spinal muscular atrophy (SMA) have been approved by the United States Food and Drug Administration and the European Medicines Agency since 2016. Although these new therapies improve the quality of life of patients who are symptomatic at first treatment, administration before the onset of symptoms is significantly more effective. As a consequence, newborn screening programs have been initiated in several countries.
View Article and Find Full Text PDFIntroduction: Haematopoietic stem cell transplantation (HSCT) involves implanting cellular elements capable of generating a new and healthy haematopoietic system. Reduced intensity conditioning (RIC) consists of an immunosuppressive treatment to facilitate a progressive implant with lower morbidity. This type of conditioning can also lead to myelosuppression, which is potentially reversible over time.
View Article and Find Full Text PDF